Verastem Inc. CEO Robert Forrester told BioWorld that the company seeks to share the upper atmosphere's "rarefied air" with small-to-mid cap biotechs that have reached the market with new oncology drugs to fly the same skies as big pharma. "These things don't happen very often," he noted. "If we are fortunate, we will be the 11th" such smaller firm since 2010 to win clearance for a promising cancer compound.